Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Advanced Solitary Fibrous Tumor
NCT02261207Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in solitary fibrous tumor (SFT), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall Response Rate by Choi Criteria at 4 years. Started Nov 2014; status: completed.
02
Drugs
axitinib
03
Conditions
solitary fibrous tumor (SFT)
Beyond the preview
Go deeper on NCT02261207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261207.